Britain moves ahead with a drug-repurposing research program that brings together big pharma and academic researchers in novel collaborations.
A pilot program in the U.K. that takes selected compounds from pharmaceutical companies’ back catalogues and gathers ideas on their potential scientific use and possible commercial development is being expanded.
The repurposing scheme, begun in 2011 and piloted by AstraZeneca PLC and the U.K.’s Medical Research Council (MRC), is...
At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.
The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.
Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.
